RMC No. 93-2024 publishes FDA-endorsed updates to the VAT-exempt list of medicines under TRAIN and CREATE Acts, including additions and deletions, effective upon FDA publication.
Businesses and tax practitioners handling pharmaceuticals must review the updated VAT-exempt list as endorsed by the Food and Drug Administration (FDA) and published by the Bureau of Internal Revenue. This update introduces significant changes for certain medicines, effective immediately upon FDA publication.
What Changed Under RMC No. 93-2024
The circular publishes the full text of the FDA letter dated June 20, 2024, which updates the list of medicines exempt from value-added tax (VAT) under Republic Act No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act). Key updates include:
1. Inclusion of medicines for cancer, high cholesterol, hypertension, and mental illness on the VAT-exempt list.
2. Deletion of certain medicines for hypertension previously covered under VAT exemption.
These changes align the VAT treatment of covered medicines with current public health priorities and legislative directives.
Who Is Affected
Manufacturers, importers, distributors, pharmacies, and healthcare providers who sell or purchase medicines listed under the VAT exemption must immediately adjust their accounting and tax reporting practices. Internal Revenue Officers (IROs) and other revenue personnel are directed to implement these changes in compliance checks, audits, and taxpayer guidance.
Effective Date and Compliance Requirements
As clarified under Q&A No. 1 of RMC No. 99-2021, the VAT exemption for the updated list of medicines is effective on the date of publication by the FDA. All affected parties should:
– Update accounting and inventory systems to reflect VAT-exempt status for newly included medicines.
– Ensure that deleted medicines are no longer claimed as VAT-exempt in tax returns.
– Maintain proper documentation and official correspondence from the FDA to substantiate VAT exemption claims during audits.
Penalties for Non-Compliance
Failure to adjust to the updated VAT-exempt list may result in assessment of VAT on previously exempted sales, penalties, and interest under the National Internal Revenue Code. Proper documentation from the FDA and adherence to the circular’s guidance are essential to avoid disputes during BIR assessments.
Practical Steps for Businesses
1. Review the full FDA list published in the circular and cross-check against your current medicine inventory.
2. Train accounting and compliance teams to correctly apply VAT-exempt treatment on invoices and tax returns.
3. Communicate updates to suppliers and customers to prevent erroneous VAT application.
4. Document all changes and retain FDA publications as evidence for internal control and tax audits.
Staying current with RMC No. 93-2024 ensures compliance with VAT regulations and prevents potential penalties. For businesses seeking guidance on proper VAT treatment, accounting adjustments, or BIR audit readiness, Ablola, Saribong & Gueco offers expert support to navigate the updated regulatory landscape. Visit MakatiLawFirm.com for specialized tax compliance assistance.